INTELGENX TECHNOLOGIES CORP., 10-Q filed on 5/14/2020
Quarterly Report
v3.20.1
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2020
May 14, 2020
Document and Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Mar. 31, 2020  
Entity Registrant Name IntelGenx Technologies Corp.  
Entity Central Index Key 0001098880  
Current Fiscal Year End Date --12-31  
Entity Filer Category Non-accelerated Filer  
Entity Common Stock, Shares Outstanding   110,259,653
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q1  
Entity Shell Company false  
Entity Small Business true  
Entity Interactive Data Current Yes  
Entity Emerging Growth Company false  
v3.20.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Current    
Cash $ 355 $ 1,332
Short-term investments 4,012 580
Accounts receivable 425 381
Prepaid expenses 145 170
Investment tax credits receivable 414 375
Inventory 350 382
Total current assets 5,701 3,220
Leasehold improvements and equipment, net 5,712 6,365
Security deposits 688 752
Operating lease right-of-use asset 606 683
Total assets 12,707 11,020
Current    
Accounts payable and accrued liabilities 1,878 1,941
Current portion of long-term debt 602 727
Current portion of operating lease liability 125 137
Convertible debentures 5,251 5,642
Total current liabilities 7,856 8,447
Long-term debt 339 470
Convertible notes 1,308 1,255
Operating lease liability 490 555
Total liabilities 9,993 10,727
Shareholders' equity    
Capital Stock, common shares, $0.00001 par value; 200,000,000 shares authorized; 110,259,652 shares issued and outstanding (2019: 93,942,652 common shares) (note 10) 1 1
Additional paid-in capital 47,950 42,635
Accumulated deficit (43,964) (41,507)
Accumulated other comprehensive loss (1,273) (836)
Total shareholders' equity 2,714 293
Total liabilities and shareholders' equity $ 12,707 $ 11,020
v3.20.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Common Stock, Par Value Per Share $ 0.00001 $ 0.00001
Common Stock, Shares Authorized 200,000,000 200,000,000
Common Stock, Shares, Issued 110,259,652 93,942,652
Common Stock, Shares, Outstanding 110,259,652 93,942,652
v3.20.1
Consolidated Statement of Shareholders' Equity (Unaudited) - 3 months ended Mar. 31, 2020 - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-In Capital [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive Loss [Member]
Total
Beginning Balance at Dec. 31, 2019 $ 1 $ 42,635 $ (41,507) $ (836) $ 293
Beginning Balance (Shares) at Dec. 31, 2019 93,942,652        
Other comprehensive income       (437) (437)
Common stock issued, net of transaction costs of $778   3,912     3,912
Common stock issued, net of transaction costs of $778 (Shares) 16,317,000        
Warrants issued, net of transaction costs of $240   1,207     1,207
Agents' warrants issued   125     125
Stock-based compensation   71     71
Net loss for the period     (2,457)   (2,457)
Ending Balance at Mar. 31, 2020 $ 1 $ 47,950 $ (43,964) $ (1,273) $ 2,714
Ending Balance (Shares) at Mar. 31, 2020 110,259,652        
v3.20.1
Consolidated Statement of Shareholders' Equity (Unaudited) (Parenthetical)
$ in Thousands
3 Months Ended
Mar. 31, 2020
USD ($)
Statement of Stockholders' Equity [Abstract]  
Common stock transaction cost $ 778
Warrants transaction cost $ 240
v3.20.1
Consolidated Statement of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Statement of Operations [Abstract]    
Total revenues $ 202 $ 416
Expenses    
Research and development expense 850 860
Selling, general and administrative expense 1,324 1,704
Depreciation of tangible assets 179 171
Total expenses 2,353 2,735
Operating loss (2,151) (2,319)
Interest income 1 29
Financing and interest expense (307) (298)
Net financing and interest expense (306) (269)
Net Loss (2,457) (2,588)
Other Comprehensive (Loss) Income    
Foreign currency translation adjustment (218) 223
Change in fair value (219) 24
Total other comprehensive income (loss) (437) 247
Comprehensive loss $ (2,894) $ (2,341)
Basic and diluted weighted average number of shares outstanding 102,908,037 93,519,140
Basic and diluted loss per common share $ (0.03) $ (0.03)
v3.20.1
Consolidated Statement of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Funds (used) provided - Operating activities    
Net loss $ (2,457) $ (2,588)
Depreciation of tangible assets 179 171
Stock-based compensation 71 86
Accretion expense 146 120
DSU expense (175) 210
Lease non-cash expense 1 3
Total Adjustment (2,235) (1,998)
Changes in non-cash items related to operations:    
Accounts receivable (44) 141
Prepaid expenses 25 67
Investment tax credits receivable (39) (102)
Accounts payable and accrued liabilities 125 (501)
Net change in non-cash items related to operations 67 (395)
Net cash used in operating activities (2,168) (2,393)
Financing activities    
Repayment of long-term debt (196) (159)
Proceeds from exercise of warrants and stock options   21
Net proceeds from public offering 5,564  
Transaction costs of public offering (320)  
Net cash provided by (used in) financing activities 5,048 (138)
Investing activities    
Additions to leasehold improvements and equipment (57) (70)
Redemption of short-term investments 581 3,731
Acquisition of short-term investments (4,532) (1,469)
Net cash (used in) provided by investing activities (4,008) 2,192
Decrease in cash (1,128) (339)
Effect of foreign exchange on cash 151 151
Cash    
Beginning of period 1,332 6,815
End of period $ 355 $ 6,627
v3.20.1
Basis of Presentation
3 Months Ended
Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation [Text Block]

1. Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal and recurring nature.

These financial statements should be read in conjunction with the audited consolidated financial statements at December 31, 2019. Operating results for the three months ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States ("U.S. GAAP"). This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. 

The consolidated financial statements include the accounts of the Company and its subsidiary companies. On consolidation, all inter-entity transactions and balances have been eliminated.

The financial statements are expressed in U.S. funds.

Management has performed an evaluation of the Company's activities through the date and time these financial statements were issued and concluded that there are no additional significant events requiring recognition or disclosure.

v3.20.1
Going Concern
3 Months Ended
Mar. 31, 2020
Going Concern [Abstract]  
Going Concern [Text Block]
2.

Going Concern

  
 

The Company has financed its operations to date primarily through public offerings of its common stock, bank loans, royalty, up-front and milestone payments, license fees, proceeds from exercise of warrants and options, research and development revenues and the sale of U.S. royalty on future sales of Forfivo XL®. The Company has devoted substantially all of its resources to its drug development efforts, conducting clinical trials to further advance the product pipeline, the expansion of its facilities, protecting its intellectual property and general and administrative functions relating to these operations. The future success of the Company is dependent on its ability to develop its product pipeline and ultimately upon its ability to attain profitable operations. As of March 31, 2020, the Company had cash and short-term investments totaling approximately $4,367. The Company does not have sufficient existing cash and short-term investments to support operations for the next year following the issuance of these financial statements.

On March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus ("COVID-19") as a global pandemic, which continues to spread throughout Canada and around the world. On March 23, 2020, the government of Quebec ordered the closure of all non-essential businesses effective March 25, 2020. Because of the nature of its operations, the Company is only partially affected by this order. The Company is aware of the impact on its business as a result of COVID-19 but uncertain as to the extent of this impact on its consolidated financial statements. This partial disruption, even temporary, may impact our operations and overall business by delaying the progress of our research and development programs and production activities. There is uncertainty as to the duration and hence the potential impact. As a result, we are unable to estimate the potential impact on our business as of the date of this filing.

 

These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans to alleviate these conditions include pursuing one or more of the following steps to raise additional funding, none of which can be guaranteed or are entirely within the Company's control:

 
 

Raise funding through the possible sale of the Company's common stock, including public or private equity financings.

   
 Raise funding through debt financing.
   
 Continue to seek partners to advance product pipeline.
   
 Initiate oral film manufacturing activities.
   
 Initiate contract oral film manufacturing activities.
 
 

If the Company is unable to raise capital when needed or on attractive terms, or if it is unable to procure partnership arrangements to advance its programs, the Company would be forced to delay, reduce or eliminate its research and development programs. The current COVID-19 pandemic could continue to have a negative impact on the stock market, including trading prices of the Company's shares and its ability to raise new capital.

  
 

The accompanying consolidated interim financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The accompanying consolidated interim financial statements do not include any adjustments or classifications that may result from the possible inability of the Company to continue as a going concern. Should the Company be unable to continue as a going concern, it may be unable to realize the carrying value of its assets and to meet its liabilities as they become due.

v3.20.1
Significant Accounting Policies
3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Significant Accounting Policies [Text Block]
3.Significant Accounting Policies
  
 Revenue Recognition
  
 

The Company may enter into licensing and collaboration agreements for product development, licensing, supply and manufacturing for its product pipeline. The terms of the agreements may include non-refundable signing and licensing fees, milestone payments and royalties on any product sales derived from collaborations. These contracts are analyzed to identify all performance obligations forming part of these contracts. The transaction price of the contract is then determined. The transaction price is allocated between all performance obligations on a residual standalone selling price basis. The stand-alone selling price is estimated based on the comparable market prices, expected cost plus margin and the Company's historical experience.

  
 

Revenue is measured based on a consideration specified in a contract with a customer, and excludes any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product or service to a customer.

  
 

Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue.

  
 

The following is a description of principal activities - separated by nature - from which the Company generates its revenue.

  
 

Research and Development Revenue

  
 

Revenues with corporate collaborators are recognized as the performance obligations are satisfied over time, and the related expenditures are incurred pursuant to the terms of the agreement.

  
 

Licensing and Collaboration Arrangements

 

 

 

Licenses are considered to be right-to-use licenses. As such, the Company recognizes the licenses revenues at a point in time, upon granting the licenses.

  
 

Milestone payments are considered variable consideration. As such, the Company estimates variable consideration at the most likely amount to which we expect to be entitled. The estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, research and other revenues in the period during which the adjustment is recognized. The process of successfully achieving the criteria for the milestone payments is highly uncertain. Consequently, there is significant risk that the Company may not earn all of the milestone payments for each of its contracts.

  
 

Royalties are typically calculated as a percentage of net sales realized by the Company's licensees of its products (including their sub-licensees), as specifically defined in each agreement. The licensees' sales generally consist of revenues from product sales of the Company's product pipeline and net sales are determined by deducting the following: estimates for chargebacks, rebates, sales incentives and allowances, returns and losses and other customary deductions in each region where the Company has licensees. Revenues arising from royalties are considered variable consideration. As such, the Company estimates variable consideration at the most likely amount to which we expect to be entitled. The estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved.

 


Leasehold Improvements and Equipment

  
 

Leasehold improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows:

 
 On the declining balance method - 
   
        Laboratory and office equipment20%
        Computer equipment30%
   
 On the straight-line method -
        Leasehold improvements

over the lease term
   
 Manufacturing equipment5 - 10 years

Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred.

 

Leases

  
 

Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: the lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably certain to be exercised, the lease term is for a major part of the remaining useful life of the asset or the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any one of these criteria.

  
 

Substantially all of the Company’s operating leases are comprised of office space and property leases and the Company does not hold any finance leases.

  
 

For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease.

  
 

The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company’s secured incremental borrowing rate for the same term as the underlying lease.

  
 

Lease payments included in the measurement of the lease liability comprise the following: the fixed noncancelable lease payments, payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease will not be terminated early.

 

 

 

Lease modifications result in remeasurement of the lease liability.

 

 

 

Lease expense for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability.

 

 

 

The Company has elected not to recognize right-of-use assets and lease liabilities for short-tern leases that have a term of 12 months or less. The effect of short-term leases on our right-of-use asset and lease liability was not material.
 

 

Recent Accounting Pronouncements

  
 

ASU 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes

  
 

The FASB issued ASU 2019-12 which removes specific exceptions to the general principles in Topic 740 in Generally Accepted Accounting Principles (GAAP). It eliminates the need for an organization to analyze whether the following apply in a given period:

  
 

-Exception to the incremental approach for intraperiod tax allocation;

  
 

-Exceptions to accounting for basis differences when there are ownership changes in foreign investments; and

  
 

-Exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses.

 
 

The ASU also improves financial statement preparers' application of income tax-related guidance and simplifies GAAP for:

  
 

-Franchise taxes that are partially based on income;

  
 

-Transactions with a government that result in a step up in the tax basis of goodwill;

  
 

-Separate financial statements of legal entities that are not subject to tax; and

  
 

-Enacted changes in tax laws in interim periods.

  
 

These amendments are effective for fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of this Statement on its consolidated financial statements.

v3.20.1
Inventory
3 Months Ended
Mar. 31, 2020
Inventory Disclosure [Abstract]  
Inventory [Text Block]
4.

Inventory

 

 

 

Inventory as at March 31, 2020 consisted of raw materials in the amount of $350 thousand (2019: $382 thousand).

v3.20.1
Leasehold Improvements and Equipment
3 Months Ended
Mar. 31, 2020
Property, Plant and Equipment [Abstract]  
Leasehold Improvements and Equipment [Text Block]

5.      Leasehold Improvements and Equipment

         

March 31,

  December 31, 
         2020  2019 
      Accumulated  Net Carrying   Net Carrying 
   Cost  Depreciation  Amount   Amount 
 Manufacturing equipment$ 4,300 $ 871 $ 3,429  $ 3,778 
 Laboratory and office equipment 1,255  817  438   498 
 Computer equipment 115  83  32   40 
 Leasehold improvements 3,058  1,245  1,813   2,049 
  $ 8,728 $ 3,016 $ 5,712  $ 6,365 

From the balance of manufacturing equipment, an amount of $1,637 thousand (2019: $1,788 thousand) represents assets which are still under construction as at March 31, 2020 and are consequently not depreciated.

v3.20.1
Bank indebtedness
3 Months Ended
Mar. 31, 2020
Bank Indebtedness [Abstract]  
Bank Indebtedness [Text Block]
6.

Bank Indebtedness

 


The Company's credit facility is subject to review annually and consists of an operating demand line of credit of up to CAD$250 thousand ($176 thousand) and corporate credits cards of up to CAD$75 thousand ($53 thousand) and $60 thousand, and foreign exchange contracts limited to CAD$425 thousand ($300 thousand). Borrowings under the operating demand line of credit bear interest at the Bank’s prime lending rate plus 2%. The credit facility and term loan (see note 8) are secured by a first ranking movable hypothec on all present and future movable property of the Company for an amount of CAD$4,250,000 ($2,996,000) plus 20%, and a 50% guarantee by Export Development Canada, a Canadian Crown corporation export credit agency. The terms of the banking agreement require the Company to comply with certain debt service coverage and debt to net worth financial covenants on an annual basis at the end of the Company's fiscal year. As at March 31, 2020, the Company has not drawn on its credit facility.

v3.20.1
Long-term Debt
3 Months Ended
Mar. 31, 2020
Other Liabilities Disclosure [Abstract]  
Long-term Debt [Text Block]
7.

Long-term Debt

  
 

The components of the Company’s debt are as follows:

 
   

March 31, 2020

  December 31, 2019 
   $  $ 
        
 Term loan facility 788  1,005 
 Secured loan 153  192 
 Total debt 941  1,197 
        
 Less: current portion 602  727 
        
 Total long-term debt 339  470 


The Company’s term loan facility consists of a total of CAD$4 million ($2.82 million) bearing interest at the Bank’s prime lending rate plus 2.50%, with monthly principal repayments of CAD$62 thousand ($44 thousand). The term loan is subject to the same security and financial covenants as the bank indebtedness (see note 7).

The secured loan has a principal balance authorized of CAD$1 million ($705 thousand) bearing interest at prime plus 7.3%, reimbursable in monthly principal payments of CAD$17 thousand ($12 thousand) from January 2017 to March 2021. In March 2020, as a result of the global pandemic, the lender granted the Company an automatic six-month moratorium of capital repayments. The loan is secured by a second ranking on all present and future property of the Company. The terms of the banking agreement require the Company to comply with certain debt service coverage and debt to net worth financial covenants on an annual basis at the end of the Company's fiscal year.

Principal repayments due in each of the next two years are as follows:

 2020441 (CAD 625)
 2021500 (CAD 710)
v3.20.1
Convertible Debentures
3 Months Ended
Mar. 31, 2020
Convertible Debt [Abstract]  
Convertible Debentures [Text Block]
8.Convertible Debentures
  
 

On July 12, 2017, the Company closed its previously announced prospectus offering (the "Offering") of convertible unsecured subordinated debentures of the Corporation (the "Debentures") for gross aggregate proceeds of CAD$6,838,000 ($4,820,000). Pursuant to the Offering, the Corporation issued an aggregate principal amount of CAD$6,838,000 ($4,820,000) of Debentures at a price of CAD$1,000 ($705) per Debenture. The Debentures will mature on June 30, 2020 and bear interest at annual rate of 8% payable semi-annually on the last day of June and December of each year, commencing on December 31, 2017. The interest may be paid in common shares at the option of the Corporation. The Debentures will be convertible at the option of the holders at any time prior to the close of business on the earlier of June 30, 2020 and the business day immediately preceding the date specified by the Corporation for redemption of Debentures. The conversion price will be CAD$1.35 ($0.95) (the "Conversion Price") per common share of the Corporation ("Share"), being a conversion rate of approximately 740 Shares per CAD$1,000 ($705) principal amount of Debentures, subject to adjustment in certain events.

  
 On August 8, 2017, the Company closed a second tranche of its prospectus Offering of convertible unsecured subordinated debentures of the Corporation for which a first closing took place on July 12, pursuant to which it had raised additional gross proceeds of CAD$762,000 ($537,000).
  
 Together with the principal amount of CAD$6,838,000 ($4,820,000) of Debentures issued on July 12, 2017, the Corporation issued a total aggregate principal amount of CAD$7,600,000 ($5,357,000) of Debentures at a price of CAD$1,000 ($705) per Debenture.
  
 The convertible debentures have been recorded as a liability. Total transactions costs in the amount of CAD$1,237,000 ($872,000) were recorded against the liability. The accretion expense for the three-month period ended March 31, 2020 amounts to CAD$121,000 ($90,000), compared to CAD$105,000 ($79,000) for the comparative period in 2019.
  
 

The components of the convertible debentures are as follows:

   March 31,  December 31, 
   2020  2019 
        
 Face value of the convertible debentures$ 5,343 $ 5,835 
 Transaction costs (872) (952)
 Accretion 780  759 
 Convertible debentures$ 5,251 $ 5,642 

 

The interest accrued on the convertible debentures for the three-month period ended March 31, 2020 amounts to CAD$152 thousand ($113 thousand) and is recorded in financing and interest expense. The interest on the convertible debentures amounted to CAD$152 thousand ($114 thousand) for the three-month period ended March 31, 2019.

v3.20.1
Convertible Notes
3 Months Ended
Mar. 31, 2020
Convertible Notes [Abstract]  
Convertible Notes [Text Block]
9.Convertible Notes
  
 

On May 8, 2018, the Company closed its previously announced offering by way of private placement (the “Offering”). In connection with the Offering, the Company issued 320 units (the “Units”) at a subscription price of $10,000 per Unit for gross proceeds of $3,200,000. A related party of the Company participated in the Offering and subscribed for an aggregate of two Units.

  
 

Each Unit is comprised of (i) 7,940 common shares of the Corporation (“Common Shares”), (ii) a $5,000 convertible 6% note (a “Note”), and (iii) 7,690 warrants to purchase common shares of the Corporation (“Warrants”). Each Note bears interest at a rate of 6% (payable quarterly, in arrears, with the first payment being due on September 1, 2018), matures on June 1, 2021 and is convertible into Common Shares at a conversion price of $0.80 per Common Share. Each Warrant entitles its holder to purchase one Common Share at a price of $0.80 per Common Share until June 1, 2021.

  
 

In connection with the Offering, the Company paid to the Agents a cash commission of approximately $157,800 in the aggregate and issued non-transferable agents’ warrants to the Agents, entitling the Agents to purchase 243,275 common shares at a price of $0.80 per share until June 1, 2021. Management has determined the value of the agents’ warrants to be $50,000.

  
 

The proceeds of the Units are attributed to liability and equity components based on the fair value of each component as follows:

 
   Gross proceeds  Transaction costs  Net proceeds 
 Common stock$ 1,627 $ 167 $ 1,460 
 Convertible notes 1,086  111  975 
 Warrants 487  50  437 
  $ 3,200 $ 328 $ 2,872 

The convertible notes have been recorded as a liability. Total transactions costs in the amount of $111 thousand were recorded against the liability. The accretion expense for the three-month period ended March 31, 2020 amounts to $53,000 (2019: $42,000).

The components of the convertible notes are as follows:

   March 31,  December 31, 
   2020  2019 
        
 Attributed value of net proceeds to convertible notes$ 975 $ 975 
 Accretion 333  280 
 Convertible note$ 1,308 $ 1,255 

The interest on the convertible notes for the three-month period ended March 31, 2020 amounts to $24,000 and is recorded in financing and interest expense (2019: $24,000).

v3.20.1
Capital Stock
3 Months Ended
Mar. 31, 2020
Stockholders' Equity Note [Abstract]  
Capital Stock [Text Block]

10.     Capital Stock
 

  March 31, 2020  December 31,  2019 
Authorized -      
200,000,000 common shares of $0.00001 par value      
  20,000,000 preferred shares of $0.00001 par value      
Issued -      
  110,259,652 (December 31, 2019 - 93,942,652) common shares$1 $1 
v3.20.1
Additional Paid-In Capital
3 Months Ended
Mar. 31, 2020
Additional Paid in Capital [Abstract]  
Additional Paid-In Capital [Text Block]
11.Additional Paid-In Capital
  
 

Public Offering

  
 

On February 11, 2020, IntelGenx announced the closing of 16,317,000 units (the "Units") at a price of CAD$0.50 ($0.35) for gross proceeds of CAD$8,158,500 ($5,751,000).

  
 

Each Unit consists of one share of common stock of the Company and one warrant entitling the holder to purchase one share of common stock of the Company at an exercise price of CAD$0.75 ($0.53) per share. The Warrants are exercisable immediately and will expire on the third anniversary of the date of their issuance. Management has determined the value attributed to common stock is $3,912 thousand and $1,207 thousand for the warrants issued, resulting in an increase in additional paid-in-capital of $5,119 thousand.

  
 

In connection with the Offering, the Company paid to the Agents a cash commission of approximately CAD$763,000 ($574,000) in the aggregate and issued non-transferable agents' warrants to the Agents, entitling the Agents to purchase 1,142,190 common shares at a price of CAD$0.75 ($0.53) per share until February 11, 2023. Management has determined the value of the agents' warrants to be $125,000, resulting in an increase in additional paid-in-capital of $125,000.

  
 

The proceeds of the Units are attributed to equity components based on the fair value of each component as follows:

           
   

Gross proceeds

  

Transaction costs

  

Net proceeds

 
 

Common stock

$ 4,690 $ 778 $

3,912

 
 

Warrants

 

1,447

  

240

  

1,207

 
  $ 6,137 $ 1,018 $

5,119

 

Stock options      

No options were granted during the three-month period ended March 31, 2020.

 

No stock options were exercised during the three-month period ended March 31, 2020.

 

On March 27, 2019, 100,000 options to purchase common stock were granted to an employee under the 2016 Stock Option Plan. The options have an exercise price of $0.69. The options granted vest over a period of 2 years at a rate of 25% every six months and expire 10 years after the grant date. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $40 thousand

 

During the three-month period ended March 31, 2019 a total of 50,000 stock options were exercised for 50,000 common shares having a par value of $0 thousand in aggregate, for cash consideration of $21 thousand, resulting in an increase in additional paid-in capital of $21 thousand.

  
 

Compensation expenses for stock-based compensation of $71 thousand and $86 thousand were recorded during the three-month periods ended March 31, 2020 and 2019, respectively. An amount of $59 thousand expensed in the three-month period ended March 31, 2020 relates to stock options granted to employees and an amount of $12 thousand relates to stock options granted to consultants. An amount of $74 thousand expensed in the three-month period ended March 31, 2019 relates to stock options granted to employees and an amount of $12 thousand relates to stock options granted to a consultant. As at March 31, 2020, the Company has $86 thousand (2019 - $416 thousand) of unrecognized stock-based compensation.

  
 

Warrants

  
 

No warrants were exercised during the three-month periods ended March 31, 2020 and 2019.

  
 

Deferred Share Units (“DSUs”)

  
 

On March 27, 2019, 271,740 DSUs have been granted under the DSU Plan.

  
 

No DSUs were granted in 2020.

  
 Performance and Restricted Share Units (“PRSUs”)
  
 

No PRSUs were granted during the three-month periods ended March 31, 2020 and 2019.

v3.20.1
Revenues
3 Months Ended
Mar. 31, 2020
Revenue from Contract with Customer [Abstract]  
Revenues [Text Block]
12.

Revenues

  
 

The following table presents our revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues:

 
   March 31, 2020  March 31, 2019 
        
 Research and development agreements$ 202 $ 416 
        

 

   The following table presents our revenues disaggregated by timing of recognition:

   March 31, 2020  March 31, 2019 
 (in U.S. $ thousands)      
 Product and services transferred at point in time$ 202 $ 372 
 Products and services transferred over time   44 
  $ 202 $ 416 

The following table presents our revenues disaggregated by geography, based on the billing addresses of our customers:

   March 31, 2020  March 31, 2019 
        
 Europe$ 202  385 
 Canada   31 
  $ 202 $ 416 


Remaining performance obligations

As at March 31, 2020, the aggregate amount of the transaction price allocated to the remaining performance obligation is $1,084 representing research and development agreements, the majority of which is expected to be recognized in the next twelve months. The Company is also eligible to receive up to $4,169 in research and development milestone payments, approximately 60% of which is expected to be recognized in the next three years, with the remaining 40% expected in the two years following; up to $28,376 in commercial sales milestone payments which are wholly dependent on the marketing efforts of our development partners. In addition, the Company is entitled to receive royalties on potential sales.

v3.20.1
Leases
3 Months Ended
Mar. 31, 2020
Leases [Abstract]  
Leases [Text Block]

13.    Leases

Substantially all our operating lease right-of-use assets and operating lease liability represents leases for office space and property to conduct our business.

The operating lease expense for the three-month period ended March 31, 2020 included in general and administrative expenses is $37 thousand. The cash outflows from operating leases for the three-month period ended March 31, 2020 was $36 thousand.

The weighted average remaining lease term and the weighted average discount rate for operating leases at March 31, 2020 were 5.9 years and 10%, respectively.

The following table reconciles the undiscounted cash flows for the operating leases as at March 31, 2020 to the operating lease liabilities recorded on the balance sheet:

  Operating Leases 
    
2020$103 
2021 139 
2022 143 
2023 144 
2024 148 
Thereafter 172 
Total undiscounted lease payments 849 
Less: Interest 234 
Present value of lease liabilities$615 

       

Current portion of operating lease liability

$125

Operating lease liability

$490
v3.20.1
Related Party Transactions
3 Months Ended
Mar. 31, 2020
Related Party Transactions [Abstract]  
Related Party Transactions [Text Block]

14.  Related Party Transactions

Included in management salaries are $10 thousand (2019 - $20 thousand) for options granted to the Chief Executive Officer, $10 thousand (2019 - $14 thousand) for options granted to the Chief Financial Officer, $10 thousand (2019 - $5 thousand) for options granted to the Vice President, Operations, $5 thousand (2019 - $8 thousand) for options granted to the Vice-President, Research and Development, $5 thousand (2019 - $8 thousand) for options granted to Vice-President, Business and Corporate Development under the 2016 Stock Option Plan.

Also included in general and administrative expense for the three-month period ended March 31, 2020 are director fees of $58 thousand (2019 - $58 thousand) and DSU recovery of $175 thousand (2019: expense of $210 thousand).

The above related party transactions have been measured at the exchange amount which is the amount of the consideration established and agreed to by the related parties.

v3.20.1
Basic and Diluted Loss Per Common Share
3 Months Ended
Mar. 31, 2020
Earnings Per Share [Abstract]  
Basic and Diluted Loss Per Common Share [Text Block]

15.  Basic and Diluted Loss Per Common Share

Basic and diluted loss per common share is calculated based on the weighted average number of shares outstanding during the period. The warrants, share-based compensation and convertible debenture and notes have been excluded from the calculation of diluted loss per share since they are anti-dilutive.

v3.20.1
Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Revenue Recognition [Policy Text Block]
 Revenue Recognition
  
 

The Company may enter into licensing and collaboration agreements for product development, licensing, supply and manufacturing for its product pipeline. The terms of the agreements may include non-refundable signing and licensing fees, milestone payments and royalties on any product sales derived from collaborations. These contracts are analyzed to identify all performance obligations forming part of these contracts. The transaction price of the contract is then determined. The transaction price is allocated between all performance obligations on a residual standalone selling price basis. The stand-alone selling price is estimated based on the comparable market prices, expected cost plus margin and the Company's historical experience.

  
 

Revenue is measured based on a consideration specified in a contract with a customer, and excludes any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product or service to a customer.

  
 

Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue.

  
 

The following is a description of principal activities - separated by nature - from which the Company generates its revenue.

  
 

Research and Development Revenue

  
 

Revenues with corporate collaborators are recognized as the performance obligations are satisfied over time, and the related expenditures are incurred pursuant to the terms of the agreement.

  
 

Licensing and Collaboration Arrangements

 

 

 

Licenses are considered to be right-to-use licenses. As such, the Company recognizes the licenses revenues at a point in time, upon granting the licenses.

  
 

Milestone payments are considered variable consideration. As such, the Company estimates variable consideration at the most likely amount to which we expect to be entitled. The estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, research and other revenues in the period during which the adjustment is recognized. The process of successfully achieving the criteria for the milestone payments is highly uncertain. Consequently, there is significant risk that the Company may not earn all of the milestone payments for each of its contracts.

  
 

Royalties are typically calculated as a percentage of net sales realized by the Company's licensees of its products (including their sub-licensees), as specifically defined in each agreement. The licensees' sales generally consist of revenues from product sales of the Company's product pipeline and net sales are determined by deducting the following: estimates for chargebacks, rebates, sales incentives and allowances, returns and losses and other customary deductions in each region where the Company has licensees. Revenues arising from royalties are considered variable consideration. As such, the Company estimates variable consideration at the most likely amount to which we expect to be entitled. The estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved.

Leasehold Improvements and Equipment [Policy Text Block]
 


Leasehold Improvements and Equipment

  
 

Leasehold improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows:

 
 On the declining balance method - 
   
        Laboratory and office equipment20%
        Computer equipment30%
   
 On the straight-line method -
        Leasehold improvements

over the lease term
   
 Manufacturing equipment5 - 10 years

Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred.

Leases [Policy Text Block]
 

Leases

  
 

Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: the lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably certain to be exercised, the lease term is for a major part of the remaining useful life of the asset or the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any one of these criteria.

  
 

Substantially all of the Company’s operating leases are comprised of office space and property leases and the Company does not hold any finance leases.

  
 

For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease.

  
 

The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company’s secured incremental borrowing rate for the same term as the underlying lease.

  
 

Lease payments included in the measurement of the lease liability comprise the following: the fixed noncancelable lease payments, payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease will not be terminated early.

 

 

 

Lease modifications result in remeasurement of the lease liability.

 

 

 

Lease expense for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability.

 

 

 

The Company has elected not to recognize right-of-use assets and lease liabilities for short-tern leases that have a term of 12 months or less. The effect of short-term leases on our right-of-use asset and lease liability was not material.
 

Recent Accounting Pronouncements [Policy Text Block]
 

Recent Accounting Pronouncements

  
 

ASU 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes

  
 

The FASB issued ASU 2019-12 which removes specific exceptions to the general principles in Topic 740 in Generally Accepted Accounting Principles (GAAP). It eliminates the need for an organization to analyze whether the following apply in a given period:

  
 

-Exception to the incremental approach for intraperiod tax allocation;

  
 

-Exceptions to accounting for basis differences when there are ownership changes in foreign investments; and

  
 

-Exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses.

 
 

The ASU also improves financial statement preparers' application of income tax-related guidance and simplifies GAAP for:

  
 

-Franchise taxes that are partially based on income;

  
 

-Transactions with a government that result in a step up in the tax basis of goodwill;

  
 

-Separate financial statements of legal entities that are not subject to tax; and

  
 

-Enacted changes in tax laws in interim periods.

  
 

These amendments are effective for fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of this Statement on its consolidated financial statements.

v3.20.1
Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment [Table Text Block]
 On the declining balance method - 
   
        Laboratory and office equipment20%
        Computer equipment30%
   
 On the straight-line method -
        Leasehold improvements

over the lease term
   
 Manufacturing equipment5 - 10 years
v3.20.1
Leasehold Improvements and Equipment (Tables)
3 Months Ended
Mar. 31, 2020
Property, Plant and Equipment [Abstract]  
Schedule of Leasehold Improvements and Equipment [Table Text Block]
         

March 31,

  December 31, 
         2020  2019 
      Accumulated  Net Carrying   Net Carrying 
   Cost  Depreciation  Amount   Amount 
 Manufacturing equipment$ 4,300 $ 871 $ 3,429  $ 3,778 
 Laboratory and office equipment 1,255  817  438   498 
 Computer equipment 115  83  32   40 
 Leasehold improvements 3,058  1,245  1,813   2,049 
  $ 8,728 $ 3,016 $ 5,712  $ 6,365 
v3.20.1
Long-term Debt (Tables)
3 Months Ended
Mar. 31, 2020
Other Liabilities Disclosure [Abstract]  
Schedule of Term loan [Table Text Block]
   

March 31, 2020

  December 31, 2019 
   $  $ 
        
 Term loan facility 788  1,005 
 Secured loan 153  192 
 Total debt 941  1,197 
        
 Less: current portion 602  727 
        
 Total long-term debt 339  470 
Schedule of Term loan principal repayments [Table Text Block]
 2020441 (CAD 625)
 2021500 (CAD 710)
v3.20.1
Convertible Debentures (Tables)
3 Months Ended
Mar. 31, 2020
Convertible Debt [Abstract]  
Schedule of Convertible Debt [Table Text Block]
   March 31,  December 31, 
   2020  2019 
        
 Face value of the convertible debentures$ 5,343 $ 5,835 
 Transaction costs (872) (952)
 Accretion 780  759 
 Convertible debentures$ 5,251 $ 5,642 
v3.20.1
Convertible Notes (Tables)
3 Months Ended
Mar. 31, 2020
Convertible Notes [Abstract]  
Schedule of Capital Units [Table Text Block]
   Gross proceeds  Transaction costs  Net proceeds 
 Common stock$ 1,627 $ 167 $ 1,460 
 Convertible notes 1,086  111  975 
 Warrants 487  50  437 
  $ 3,200 $ 328 $ 2,872 
Schedule of Components of the Convertible Notes [Table Text Block]
   March 31,  December 31, 
   2020  2019 
        
 Attributed value of net proceeds to convertible notes$ 975 $ 975 
 Accretion 333  280 
 Convertible note$ 1,308 $ 1,255 
v3.20.1
Capital Stock (Tables)
3 Months Ended
Mar. 31, 2020
Stockholders' Equity Note [Abstract]  
Schedule of Stock by Class [Table Text Block]
  March 31, 2020  December 31,  2019 
Authorized -      
200,000,000 common shares of $0.00001 par value      
  20,000,000 preferred shares of $0.00001 par value      
Issued -      
  110,259,652 (December 31, 2019 - 93,942,652) common shares$1 $1 
v3.20.1
Additional Paid-In Capital (Tables)
3 Months Ended
Mar. 31, 2020
Additional Paid in Capital [Abstract]  
Schedule Of Proceeds Of Equity Components Based On Fair Value Under Public Offering [Table Text Block]
           
   

Gross proceeds

  

Transaction costs

  

Net proceeds

 
 

Common stock

$ 4,690 $ 778 $

3,912

 
 

Warrants

 

1,447

  

240

  

1,207

 
  $ 6,137 $ 1,018 $

5,119

 
v3.20.1
Revenues (Tables)
3 Months Ended
Mar. 31, 2020
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue [Table Text Block]
   March 31, 2020  March 31, 2019 
        
 Research and development agreements$ 202 $ 416 
        
Schedule of Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]
   March 31, 2020  March 31, 2019 
 (in U.S. $ thousands)      
 Product and services transferred at point in time$ 202 $ 372 
 Products and services transferred over time   44 
  $ 202 $ 416 
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]
   March 31, 2020  March 31, 2019 
        
 Europe$ 202  385 
 Canada   31 
  $ 202 $ 416 
v3.20.1
Leases (Tables)
3 Months Ended
Mar. 31, 2020
Leases [Abstract]  
Schedule of undiscounted cash flows for the operating leases [Table Text Block]
  Operating Leases 
    
2020$103 
2021 139 
2022 143 
2023 144 
2024 148 
Thereafter 172 
Total undiscounted lease payments 849 
Less: Interest 234 
Present value of lease liabilities$615 
Schedule of operating lease liabilities [Table Text Block]

Current portion of operating lease liability

$125

Operating lease liability

$490
v3.20.1
Going Concern (Narrative) (Details)
$ in Thousands
Mar. 31, 2020
USD ($)
Going Concern [Line Items]  
Cash and short-term investments $ 4,367
v3.20.1
Inventory (Narrative) (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Mar. 31, 2019
Inventory Disclosure [Abstract]    
Raw materials inventory $ 350 $ 382
v3.20.1
Leasehold Improvements and Equipment (Narrative) (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Net $ 5,712 $ 6,365
Asset not yet in service [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Net $ 1,637 $ 1,788
v3.20.1
Bank indebtedness (Narrative) (Details) - 3 months ended Mar. 31, 2020
CAD ($)
USD ($)
Line of Credit Facility [Line Items]    
Line of Credit Facility, Interest Rate Description Bank’s prime lending rate plus 2%  
Line of Credit Facility, Collateral The credit facility and term loan (see note 8) are secured by a first ranking movable hypothec on all present and future movable property of the Company for an amount of CAD$4,250,000 ($2,996,000) plus 20%, and a 50% guarantee by Export Development Canada, a Canadian Crown corporation export credit agency.  
Line Of Credit Facility, Collateral Amount $ 4,250,000 $ 2,996,000
Line Of Credit Facility, Collateral Percentage 20.00%  
Line Of Credit Facility, Guarantee Percentage By Export Development Canada 50.00%  
Line of Credit [Member]    
Line of Credit Facility [Line Items]    
Long-term Line of Credit $ 250,000 176,000
Corporate Credit Cards [Member]    
Line of Credit Facility [Line Items]    
Long-term Line of Credit 75,000 53,000
Corporate Credit Cards 2 [Member]    
Line of Credit Facility [Line Items]    
Long-term Line of Credit   60,000
Foreign Exchange Contract [Member]    
Line of Credit Facility [Line Items]    
Long-term Line of Credit $ 425,000 $ 300,000
v3.20.1
Long-term Debt (Narrative) (Details)
3 Months Ended
Mar. 31, 2020
CAD ($)
Mar. 31, 2020
USD ($)
Mar. 31, 2020
USD ($)
Aug. 08, 2017
CAD ($)
Aug. 08, 2017
USD ($)
Jul. 12, 2017
CAD ($)
Jul. 12, 2017
USD ($)
Debt Instrument [Line Items]              
Debt Instrument, Face Amount       $ 7,600,000 $ 5,357,000 $ 6,838,000 $ 4,820,000
Term loan facility [Member]              
Debt Instrument [Line Items]              
Debt Instrument, Face Amount $ 4,000,000   $ 2,820,000        
Debt Instrument, Interest Rate Terms Bank’s prime lending rate plus 2.50% Bank’s prime lending rate plus 2.50%          
Debt Instrument, Periodic Payment $ 62,000 $ 44,000          
Secured Loan [Member]              
Debt Instrument [Line Items]              
Debt Instrument, Face Amount $ 1,000,000   $ 705,000        
Debt Instrument, Interest Rate Terms bearing interest at prime plus 7.3% bearing interest at prime plus 7.3%          
Debt Instrument, Periodic Payment $ 17,000 $ 12,000          
v3.20.1
Convertible Debentures (Narrative) (Details)
3 Months Ended 12 Months Ended
Aug. 08, 2017
CAD ($)
Aug. 08, 2017
USD ($)
Jul. 12, 2017
CAD ($)
$ / shares
shares
Jul. 12, 2017
USD ($)
Mar. 31, 2020
CAD ($)
Mar. 31, 2020
USD ($)
Mar. 31, 2019
CAD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2019
USD ($)
May 08, 2018
$ / shares
Aug. 08, 2017
USD ($)
Jul. 12, 2017
USD ($)
$ / shares
shares
Convertible Debt [Abstract]                        
Net proceeds from issuance of convertible debentures $ 762,000 $ 537,000 $ 6,838,000 $ 4,820,000                
Aggregate principal amount $ 7,600,000   6,838,000               $ 5,357,000 $ 4,820,000
Proceeds from Convertible Debt, amount per instrument     $ 1,000 $ 705                
Debt Instrument, Interest Rate     8.00%                 8.00%
Debt Instrument, Convertible, Conversion Price | (per share)     $ 1.35             $ 0.80   $ 0.95
Debt Instrument, Convertible, Number of shares per instrument     740                 740
Transaction costs         $ 1,237,000 $ 872,000     $ 952,000      
Accretion Expense         121,000 90,000 $ 105,000 $ 79,000        
Interest on Convertible Debt, Net of Tax         $ 152,000 $ 113,000 $ 152,000 $ 114,000        
v3.20.1
Convertible Notes (Narrative) (Details)
3 Months Ended
May 08, 2018
USD ($)
$ / shares
shares
Mar. 31, 2020
USD ($)
shares
Mar. 31, 2019
USD ($)
Jul. 12, 2017
$ / shares
Jul. 12, 2017
$ / shares
Debt Instrument [Line Items]          
Stock Issued During Period, Shares, Conversion of Units | shares 320        
Subscription Price of Units $ 10,000        
Stock Issued During Period, Value, Conversion of Units $ 3,200,000        
Warrants Issued During Period, Warrants | shares 7,690        
Interest Rate on Convertible Note 6.00%        
Debt Instrument, Convertible, Conversion Price | (per share) $ 0.80     $ 1.35 $ 0.95
Sale of Stock, Price Per Share | $ / shares $ 0.80        
Commission Paid to Agents $ 157,800        
Stock Issued During Period, Shares, Issued for Services | shares 243,275        
Equity Issuance, Per Share Amount | $ / shares $ 0.80        
Warrants Issued During Period, Value $ 50,000        
Financing Interest Expense   $ 24,000 $ 24,000    
Accretion Expense   $ 146,000 120,000    
Convertible Debt Securities [Member]          
Debt Instrument [Line Items]          
Stock Issued During Period, Shares, Conversion of Convertible Securities | shares   7,940      
Stock Issued During Period, Value, Conversion of Convertible Securities   $ 5,000      
Interest Rate on Convertible Note   6.00%      
Convertible debt [Member]          
Debt Instrument [Line Items]          
Transactions Costs of Convertible Notes   $ 111,000      
Accretion Expense   $ 53,000 $ 42,000    
v3.20.1
Additional Paid-In Capital (Narrative) (Details)
1 Months Ended 3 Months Ended
Feb. 11, 2020
CAD ($)
$ / shares
shares
Feb. 11, 2020
USD ($)
$ / shares
shares
May 08, 2018
USD ($)
Mar. 27, 2019
USD ($)
$ / shares
shares
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
shares
Mar. 31, 2020
$ / shares
Mar. 31, 2020
$ / shares
Feb. 11, 2020
USD ($)
$ / shares
Schedule of Additional Paid In Capital [Line Items]                  
Stock based compensation         $ 71,000 $ 86,000      
Proceeds from Issuance Initial Public Offering         5,564,000        
Commission Paid to Agents     $ 157,800            
Warrants Issued During Period, Value     $ 50,000            
IPO [Member]                  
Schedule of Additional Paid In Capital [Line Items]                  
Number of units issued | shares 16,317,000 16,317,000              
Units issued, price per unit | (per share) $ 0.50               $ 0.35
Warrants, grants during period, exercise price | (per share)             $ 0.75 $ 0.53  
Proceeds from Issuance Initial Public Offering $ 8,158,500 $ 5,751,000              
Fair value of common stock and warrant issued   $ 5,119,000              
Commission Paid to Agents $ 763,000               $ 574,000
Agents warrants granted during period | shares 1,142,190 1,142,190              
Agents warrants granted during period, exercise price | (per share) $ 0.75 $ 0.53              
Agent warrants issued during period, value   $ 125,000              
Stock options [Member]                  
Schedule of Additional Paid In Capital [Line Items]                  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares           50,000      
Options exercised           $ 21,000      
Stock Issued During Period, Value, Issued for Services           0      
Employees and Directors [Member]                  
Schedule of Additional Paid In Capital [Line Items]                  
Stock based compensation         59,000 74,000      
Common Stock [Member] | IPO [Member]                  
Schedule of Additional Paid In Capital [Line Items]                  
Fair value of common stock and warrant issued   3,912,000              
Warrant [Member] | IPO [Member]                  
Schedule of Additional Paid In Capital [Line Items]                  
Fair value of common stock and warrant issued   $ 1,207,000              
Additional Paid-In Capital [Member]                  
Schedule of Additional Paid In Capital [Line Items]                  
Increase in additional paid-in-capital         21,000        
2016 Stock Option Plan [Member] | Employee [Member] | Stock options [Member]                  
Schedule of Additional Paid In Capital [Line Items]                  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares       100,000          
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares       $ 0.69          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term       2 years          
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage       25.00%          
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period       10 years          
Stock Granted, Value, Share-based Compensation, Gross       $ 40,000          
Stock options granted to consultant [Member]                  
Schedule of Additional Paid In Capital [Line Items]                  
Stock based compensation         12,000 12,000      
Unrecognized stock-based compensation [Member]                  
Schedule of Additional Paid In Capital [Line Items]                  
Stock based compensation         $ 86,000 $ 416,000      
Deferred Share Units [Member]                  
Schedule of Additional Paid In Capital [Line Items]                  
Deferred Share Units Grants in Period | shares       271,740          
v3.20.1
Revenues (Narrative) (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2020
USD ($)
Revenue from Contract with Customer [Abstract]  
Transaction price allocated to the remaining performance obligation $ 1,084
Research and development milestone payments $ 4,169
Percentages of recognized in next three year 60.00%
Percentages of remaining recognized in next two years 40.00%
Commercial sales milestone payments $ 28,376
v3.20.1
Leases (Narrative) (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2020
USD ($)
Leases [Abstract]  
Operating lease expense $ 37
Operating Lease, Payments $ 36
Weighted average remaining lease term 5 years 10 months 24 days
Weighted average discount rate for operating leases 10.00%
v3.20.1
Related Party Transactions (Narrative) (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Options granted to Chief Executive Officer [Member]    
Related Party Transaction [Line Items]    
Salaries, Wages and Officers' Compensation $ 10 $ 20
Options granted to Chief Financial Officer [Member]    
Related Party Transaction [Line Items]    
Salaries, Wages and Officers' Compensation 10 14
Options granted to former Vice President, Operations [Member]    
Related Party Transaction [Line Items]    
Salaries, Wages and Officers' Compensation 10 5
Options Granted To Vice President Research And Development [Member]    
Related Party Transaction [Line Items]    
Salaries, Wages and Officers' Compensation 5 8
Options granted to Vice- President, Business and Corporate Development [Member]    
Related Party Transaction [Line Items]    
Salaries, Wages and Officers' Compensation 5 8
Director fees [Member]    
Related Party Transaction [Line Items]    
Salaries, Wages and Officers' Compensation 58 58
Deferred Share Units [Member]    
Related Party Transaction [Line Items]    
Salaries, Wages and Officers' Compensation $ (175) $ 210
v3.20.1
Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment (Details)
3 Months Ended
Mar. 31, 2020
Laboratory and office equipment [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Depreciation Methods declining balance method
Property Plant and Equipment, Estimated Useful Live Depreciation Methods Percentage 20.00%
Computer equipment [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Depreciation Methods declining balance method
Property Plant and Equipment, Estimated Useful Live Depreciation Methods Percentage 30.00%
Leasehold improvements [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Depreciation Methods straight-line method
Property Plant And Equipment, Estimated Useful Live Depreciation Methods Description over the lease term
Manufacturing equipment [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Depreciation Methods straight-line method
Manufacturing equipment [Member] | Minimum [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 5 years
Manufacturing equipment [Member] | Maximum [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 10 years
v3.20.1
Leasehold improvements and Equipment - Schedule of Leasehold Improvements and Equipment (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Property, Plant and Equipment [Line Items]    
Cost $ 8,728  
Accumulated Depreciation 3,016  
Property, Plant and Equipment, Net Carrying Amount 5,712 $ 6,365
Manufacturing equipment [Member]    
Property, Plant and Equipment [Line Items]    
Cost 4,300  
Accumulated Depreciation 871  
Property, Plant and Equipment, Net Carrying Amount 3,429 3,778
Laboratory and office equipment [Member]    
Property, Plant and Equipment [Line Items]    
Cost 1,255  
Accumulated Depreciation 817  
Property, Plant and Equipment, Net Carrying Amount 438 498
Computer equipment [Member]    
Property, Plant and Equipment [Line Items]    
Cost 115  
Accumulated Depreciation 83  
Property, Plant and Equipment, Net Carrying Amount 32 40
Leasehold improvements [Member]    
Property, Plant and Equipment [Line Items]    
Cost 3,058  
Accumulated Depreciation 1,245  
Property, Plant and Equipment, Net Carrying Amount $ 1,813 $ 2,049
v3.20.1
Long-term Debt - Schedule of Term loan (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Other Liabilities Disclosure [Abstract]    
Term loan facility $ 788 $ 1,005
Secured loan 153 192
Total debt 941 1,197
Less: current portion 602 727
Total long-term debt $ 339 $ 470
v3.20.1
Long-term Debt - Schedule of Term loan principal repayments (Details) - Mar. 31, 2020
$ in Thousands, $ in Thousands
CAD ($)
USD ($)
Other Liabilities Disclosure [Abstract]    
2020 $ 625 $ 441
2021 $ 710 $ 500
v3.20.1
Convertible Debentures - Schedule of Convertible Debt (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2020
CAD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Convertible Debt [Abstract]      
Face value of the convertible debentures   $ 5,343 $ 5,835
Transaction costs $ (1,237,000) (872) (952)
Accretion   780 759
Convertible debentures   $ 5,251 $ 5,642
v3.20.1
Convertible Notes - Schedule of Capital Units (Details) - Offering [Member]
$ in Thousands
May 08, 2018
USD ($)
Debt Instrument [Line Items]  
Gross proceeds $ 3,200
Transaction costs 328
Net proceeds 2,872
Common stock [Member]  
Debt Instrument [Line Items]  
Gross proceeds 1,627
Transaction costs 167
Net proceeds 1,460
Warrants [Member]  
Debt Instrument [Line Items]  
Gross proceeds 487
Transaction costs 50
Net proceeds 437
Convertible notes [Member]  
Debt Instrument [Line Items]  
Gross proceeds 1,086
Transaction costs 111
Net proceeds $ 975
v3.20.1
Convertible Notes - Schedule of Components of the Convertible Notes (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Convertible Notes [Abstract]    
Attributed value of net proceeds to convertible notes $ 975 $ 975
Accretion 333 280
Convertible notes $ 1,308 $ 1,255
v3.20.1
Capital Stock - Schedule of Stock by Class (Details) - USD ($)
$ / shares in Units, $ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Common Stock, Shares Authorized 200,000,000 200,000,000
Common Stock, Par or Stated Value Per Share $ 0.00001 $ 0.00001
Preferred Stock, Shares Authorized 20,000,000 20,000,000
Preferred Stock, Par or Stated Value Per Share $ 0.00001 $ 0.00001
Common Stock, Shares, Issued 110,259,652 93,942,652
Common Stock, Value, Issued $ 1 $ 1
v3.20.1
Additional Paid-In Capital - Schedule of proceeds of the Units (Details) - IPO [Member]
$ in Thousands
Feb. 11, 2020
USD ($)
Schedule of Additional Paid In Capital [Line Items]  
Gross proceeds $ 6,137
Transaction costs 1,018
Net proceeds